Phase 3 N=760 Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=599 Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)
Infection · Surgical Site Infection
Primary: Percentage of Participants With Success of Prophylaxis — 90.4; 90.3 percentage of participants
Phase 3 N=301 PGL4001 Versus GnRH-agonist in Uterine Myomas
Uterine Myomas
Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…
Phase 3 N=111 Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
Phenylketonuria
Primary: Tabulation of the Incidence and Frequency of All AEs and SAEs That Occur Throughout the Study. — 83.8; 33.3; 6.3; 0.9 percentage of subjects reporting events
Phase 3 N=241 PGL4001 Versus Placebo in Uterine Myomas
Uterine Myomas
Primary: Co-primary Endpoint: Percentage of Subjects With Reduction in Uterine Bleeding Defined as a Pictorial Blood-loss Assessment Chart (PBAC) Score <75 at End-of-treatment…
Phase 3 N=687 Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response (SVR) — 71.5; 70.9 percentage of participants
Phase 3 N=103 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion
Cervical Intraepithelial Neoplasia
Primary: Endocervical Margin Not Free of Disease. — 8; 10 participants
Phase 3 N=110 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
Endogenous Anterior Uveitis
Primary: Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14 — 2.6; 2.6; -2.2; -2.0 Units on a scale
Phase 3 N=132 A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers — 737.79; 792.78; 768.04; 777.71 nmol/L
Phase 3 N=837 Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
Essential Hypertension
Primary: Percentage of Participants With at Least 1 Adverse Event — 78.5; 76.4 percentage of participants
Phase 3 N=60 A Human Trial to Evaluate the Effects of Chungkookjang on Histamine-induced Wheal Size in Healthy Subjects
Healthy Subjects
Primary: Changes in Histamine-induced Wheal Size — 14.9; 14.9; 14.1; 16.5 mm^2
Phase 3 N=163 Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old
Nasolacrimal Duct Obstruction
Primary: Proportion of Participants With Treatment Success — 0.92; 0.82 proportion of participants — p=0.09
Phase 3 N=96 Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration
Gingival Recession
Primary: Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site. — 95.3 percentage of participants — p=<0.0001
Phase 3 N=321 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Preterm Birth
Primary: Newborn Respiratory Distress Syndrome (RDS) — 44; 18 Twins
Phase 3 N=106 Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
Hepatitis B Virus (HBV)
Primary: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72 — 90.0; 88.1; 0; 0 percentage of participants — p=< 0.001